obinutuzumab (gazyva) Report issue

Biologics mAb Orphan Drug FDA Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. It was originated by GlycArt Biotechnology AG and developed by Roche.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$4103.6629

United States

$4690.1600 - $6417.4300
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

afutuzumab | ga101 | ga 101 | ga-101 | ga101 antibody | gazyva | gazyvaro | humabcd20 | humab | immunoglobulin g1, anti-(human cd20 (antigen)) (human-mouse monoclonal ga101 heavy chain), disulfide with human-mouse monoclonal ga101 kappa-chain, dimer | obinutuzumab | r 7159 | r-7159 | r7159 cpd | rg-7159 | ro5072759 | ro 5072759 | ro-5072759 | ro-5072759 humab

Organizations (130)

Research & Development (130)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (57)

Approved Indications (1)


 

Leukemia, Lymphocytic, Chronic, B-Cell

Experimental Indications - Clinical Trial Phases 1-4 (57)


 

Anemia (Phase 1/Phase 2)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 2)

B-Lymphocytes (Phase 1)

Breast Neoplasms (Phase 1)

Bronchiectasis (Phase 1)

Burkitt Lymphoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 1)

Colorectal Neoplasms (Phase 1/Phase 2)

Cyclin D1 (Phase 2)

Drug Therapy (Phase 2)

Fatigue (Phase 2)

Fever (Phase 2)

Geriatrics (Phase 2)

Glomerulonephritis, Membranous (Phase 2)

Graft vs Host Disease (Phase 2)

Granulomatosis with Polyangiitis (Phase 2)

Hodgkin Disease (Phase 1)

Infusions, Intravenous (Phase 2)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 1)

Leukemia (Phase 2)

Leukemia, B-Cell (Phase 1)

Leukemia, Hairy Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell ()

Leukemia, Lymphoid (Phase 3)

Leukemia, Myeloid, Acute (Phase 1)

Leukemia, Prolymphocytic (Phase 1)

Leukemia, Prolymphocytic, B-Cell (Phase 1/Phase 2)

Lupus Erythematosus, Systemic (Phase 3)

Lupus Nephritis (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 3)

Lymphoma, Follicular (Phase 4)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 3)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 3)

Lymphoma, T-Cell, Peripheral (Phase 1)

Lymphoproliferative Disorders (Phase 2)

Melanoma (Phase 1)

Microscopic Polyangiitis (Phase 2)

Mycosis Fungoides (Phase 1)

Neoplasms ()

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Sclerosis (Phase 2)

Splenomegaly (Phase 2)

Sweat (Phase 2)

Therapeutics (Phase 2)

Tissues (Phase 2)

Translocation, Genetic (Phase 2)

Transplantation (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 228
  • # of Trial Organizations: 130

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue